David A. Siegel Allakos Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allakos Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 30,500 shares of ALLK stock, worth $30,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,500

Previous 29,800 2.35%

Holding current value

$30,500

Previous $81,000 53.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $714 - $2,261	700 Added 2.35%	30,500 $38,000
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $19,780 - $36,570	-11,500 Reduced 27.85%	29,800 $81,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $5.55 $38,553 - $100,455	-18,100 Reduced 30.47%	41,300 $93,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $69,840 - $101,850	-19,400 Reduced 24.62%	59,400 $258,000
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $112,660 - $216,674	-26,200 Reduced 24.95%	78,800 $350,000

Q4 2022 Feb 14, 2023	SELL	$5.97 - $8.42 $657,297 - $927,042	-110,100 Reduced 51.19%	105,000 $884,000
Q3 2022 Nov 14, 2022	SELL	$3.02 - $5.84 $2.11 Million - $4.08 Million	-698,600 Reduced 76.46%	215,100 $1.32 Million
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $763,620 - $1.8 Million	293,700 Added 47.37%	913,700 $2.86 Million
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $3 Million - $5.79 Million	589,800 Added 1952.98%	620,000 $3.53 Million
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $44,460 - $581,828	-5,200 Reduced 14.69%	30,200 $296,000
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $3.41 Million - $4.91 Million	-44,500 Reduced 55.69%	35,400 $3.75 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $2.77 Million - $3.71 Million	32,500 Added 68.57%	79,900 $6.82 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $5.2 Million - $7.28 Million	47,400 New	47,400 $5.44 Million

Others Institutions Holding ALLK

# of Institutions

104

Shares Held

77.4M

Call Options Held

70.7K

Put Options Held

2.8K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $84.7M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account